公司名称 :
产品类型 :
产品名称 :
目录 :
规格 :
1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))
价格 :
更多信息或购买 :
文章摘录数: 29
Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60 pubmed 出版商
Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014;14:696 pubmed 出版商
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, et al. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer. 2014;110:26-33 pubmed 出版商
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13:263 pubmed 出版商
Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013;108:1316-23 pubmed 出版商
Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. 2013;19:1884-93 pubmed 出版商
Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18:6011-22 pubmed 出版商
Hansen T, Andersen C, Nielsen B, Spindler K, Sørensen F, Lindebjerg J, et al. Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett. 2011;2:1101-1106 pubmed
Sleijfer S, Gorlia T, Lamers C, Burger H, Blay J, Le Cesne A, et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer. 2012;107:639-45 pubmed 出版商
Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012;59:442-9 pubmed 出版商
Eskens F, de Jonge M, Bhargava P, Isoe T, Cotreau M, Esteves B, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17:7156-63 pubmed 出版商
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med. 2011;9:120 pubmed 出版商
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011;31:2589-95 pubmed
DuBois S, Shusterman S, Ingle A, Ahern C, Reid J, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011;17:5113-22 pubmed 出版商
de Groot J, Piao Y, Tran H, Gilbert M, Wu H, Liu J, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011;17:4872-81 pubmed 出版商
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262-9 pubmed 出版商
Farace F, Gross Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104:1144-50 pubmed 出版商
Konings I, de Jonge M, Burger H, van der Gaast A, van Beijsterveldt L, Winkler H, et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer. 2010;103:987-92 pubmed 出版商
Hansen T, Sørensen F, Spindler K, Olsen D, Andersen R, Lindebjerg J, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch. 2010;456:251-60 pubmed 出版商
Wong N, Buckman R, Clemons M, Verma S, Dent S, Trudeau M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial . J Clin Oncol. 2010;28:723-30 pubmed 出版商
Hanrahan E, Lin H, Kim E, Yan S, Du D, McKee K, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28:193-201 pubmed 出版商
Guo Q, Carrero J, Yu X, Barany P, Qureshi A, Eriksson M, et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant. 2009;24:3468-73 pubmed 出版商
Zhu A, Sahani D, Duda D, di Tomaso E, Ancukiewicz M, Catalano O, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-35 pubmed 出版商
Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil Steril. 2010;94:52-7 pubmed 出版商
Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278-84 pubmed 出版商
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6 pubmed 出版商
Saltz L, Rosen L, Marshall J, Belt R, Hurwitz H, Eckhardt S, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9 pubmed
Norden Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643-50 pubmed
Wallner W, Sengenberger R, Strick R, Strissel P, Meurer B, Beckmann M, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112:51-7 pubmed
SKU号 :
产品名称 :
规格 :
1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))
描述 :
The Human VEGFR2/KDR Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGFR2/KDR/Flk-1 in cell culture supernates (100 ul), cell lysates (100 ul), serum (20 ul), edta plasma (20 ul), heparin plasma (20 ul).
靶标 :
类别 :
物种活性 :
基因符号 :
Kit Type :
Solid Phase Sandwich ELISA
Assay Length :
样品类型 :
Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)
敏感性 :
78.10 - 5000 pg/mL
范围 :
Quantitate VEGFR2/KDR/Flk-1 down to 11.4 pg/mL
应用 :
价格 :
又名 :
CD309, CD309 antigen, EC 2.7.10, EC, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2
储存 :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
更多信息或购买 :
21 52380373
公司总部: 美国
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.